Trial reportBlood2012
Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial.
Trial report in Blood, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 7 syntheses or guidelines pooled it, 124 citations in OpenAlex.
- Low-molecular-weight heparin for the prevention of preeclampsia in high-risk pregnancies without thrombophilia: a systematic review and meta-analysis.BMC pregnancy and childbirth · 2024Pooled it
- Pravastatin in preeclampsia: A meta-analysis and systematic review.Frontiers in medicine · 2022Pooled it
- Effectiveness of the use of Low Molecular Heparin in patients with repetition abortion history: Systematic review and meta-analysis.JBRA assisted reproduction · 2021Pooled it
- Care prior to and during subsequent pregnancies following stillbirth for improving outcomes.The Cochrane database of systematic reviews · 2018Pooled it
- Antithrombotic Treatment for Recurrent Miscarriage: Bayesian Network Meta-Analysis and Systematic Review.Medicine · 2015Pooled it
- Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia.The Cochrane database of systematic reviews · 2014Pooled it
- Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction.The Cochrane database of systematic reviews · 2013Pooled it
- Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a prior history - an open-label randomised trial (the EPPI trial): study protocol.BMC pregnancy and childbirth · 2016Trial
- Article
- Comparative effectiveness of pharmacological treatments for fetal growth restriction: a network meta-analysis.Frontiers in pharmacology · 2026Review
- Network meta-analysis: comparative efficacy of diverse aspirin dosages and heparin in mitigating placenta-mediated pregnancy complications.BMC pregnancy and childbirth · 2025Article
- Kidney health outcomes of hypertensive disorders of pregnancy.Nature reviews. Nephrology · 2025Review
- Low-Molecular-Weight Heparin in Preeclampsia: Effects on Biomarkers and Prevention: A Narrative Review.Biomedicines · 2025Review
- Recurrent Pregnancy Loss Etiology, Risk Factors, Diagnosis, and Management. Fresh Look into a Full Box.Journal of clinical medicine · 2023Review
- Article
- Overexpression of lncRNA EPB41L4A-AS1 Induces Metabolic Reprogramming in Trophoblast Cells and Placenta Tissue of Miscarriage.Molecular therapy. Nucleic acids · 2019Article
- The risk of cesarean delivery after labor induction among women with prior pregnancy complications: a subgroup analysis of the AFFIRM study.BMC pregnancy and childbirth · 2019Article
- Comparison of 2 approaches in management of pregnant women with inherited trombophilias: Prospective analytical cohort study.Medicine · 2019Observational
- Autophagy is a new protective mechanism against the cytotoxicity of platinum nanoparticles in human trophoblasts.Scientific reports · 2019Article
- Aspirin and heparin for the prevention of pre-eclampsia: protocol for a systematic review and network meta-analysis.BMJ open · 2019Article
Corrections and comments
- Commented on by
Authors and funding
18 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To assess whether antithrombotic prophylaxis with low-molecular-weight heparin effectively prevents recurrence of late pregnancy complications, 135 women with previous history of preeclampsia, hemolytic anemia, elevated liver enzymes and low platelet count syndrome, intrauterine fetal death, fetal growth restriction, or placental abruption who had been referred within the 12th gestational week were randomized to medical surveillance alone (n = 68) or combined to open-label nadroparin (3800 IU daily subcutaneous injections) treatment (n = 67) in the setting of a randomized, parallel-group, superiority trial, run in Italy from April 2007 to April 2010. Primary outcome was a composite end point of late-pregnancy complications. Analysis was by intention to treat. The study was stopped for futility at the time of the first planned interim analysis. Among the 128 women eventually available for final analyses, 13 of the 63 (21%) randomized to nadroparin compared with 12 of the 65 (18%) on medical surveillance alone progressed to the primary end point. The absolute event risk difference between treatment arms (2.2; -1.6 to 16.0) was not statistically significant (P = .76). Thus, nadroparin did not prevent late-pregnancy complications in women at risk of recurrence. This finding challenges the role of antithrombotic prophylaxis with low-molecular-weight heparin in the prevention of recurrent late pregnancy complications The trial was registered at http://ricerca-clinica.agenziafarmaco.it as EudraCT 2006-004205-26.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.